Stent Graft Market Research Report, Analysis and Forecast – (2021 – 2027)

License Type

Clear

Rising Burden of Aneurysms Driving the Stent Graft Market

The Stent Graft Market is experiencing significant momentum, primarily fueled by the increasing global prevalence of abdominal and thoracic aortic aneurysms. For instance, abdominal aortic aneurysms alone affect over 200,000 people in the United States annually, as per data consolidated by Datavagyanik. The steady rise in geriatric populations, particularly across North America and Europe, is translating into a higher incidence of vascular disorders requiring minimally invasive treatment solutions like stent grafts. These devices provide structural support to weakened blood vessel walls, reducing the risk of rupture and associated mortality.

The increasing awareness and early diagnostic capabilities, coupled with advanced imaging technologies, are also contributing to a proactive treatment approach. For example, the widespread adoption of CT angiography has enabled earlier identification of aneurysms, thereby elevating the adoption of endovascular repair procedures. Consequently, the Stent Graft Market is poised for robust growth as healthcare systems prioritize preventative vascular interventions.

Technological Advancements Revolutionizing the Stent Graft Market

Innovation continues to be a cornerstone of the evolving Stent Graft Market. The development of fenestrated and branched stent grafts has significantly improved patient outcomes in complex aortic anatomies. These next-generation grafts offer custom-designed solutions tailored to patient-specific anatomical needs. Datavagyanik highlights that such innovations are reducing the need for open surgical procedures, which historically carried higher morbidity rates.

For instance, the introduction of bioengineered stent grafts with drug-eluting properties or biodegradable components is enhancing biocompatibility and reducing restenosis. The use of 3D printing in developing patient-specific stent grafts is also creating a shift in the manufacturing paradigm. These advancements are not only improving procedural success rates but also contributing to the expanded application of stent grafts in previously inoperable cases, thereby boosting overall market demand.

Growing Preference for Minimally Invasive Procedures Propelling the Stent Graft Market

Minimally invasive techniques are increasingly preferred by both surgeons and patients due to shorter recovery times, lower complication rates, and reduced hospital stays. The Stent Graft Market is benefiting directly from this clinical shift, particularly in the context of endovascular aneurysm repair (EVAR) and thoracic endovascular aortic repair (TEVAR).

According to Datavagyanik, EVAR procedures have witnessed an annual growth rate exceeding 6% over the past five years in the United States alone. This rise is attributed to favorable reimbursement policies, improved training programs for vascular surgeons, and the rising demand from aging patient demographics. For instance, over 80% of AAA (Abdominal Aortic Aneurysm) repairs in developed nations are now performed using endovascular approaches, directly increasing the demand for stent graft devices.

Strategic Collaborations and M&A Activities Shaping the Stent Graft Market

The Stent Graft Market is witnessing a dynamic phase of consolidation, with key players engaging in mergers, acquisitions, and strategic alliances. These partnerships are aimed at expanding technological capabilities, geographic reach, and product portfolios. For example, the acquisition of Endospan Ltd. by Terumo Corporation has strengthened Terumo’s presence in the thoracic aortic stent graft segment by integrating Endospan’s innovative NEXUS™ technology.

Moreover, joint ventures between device manufacturers and healthcare providers are facilitating clinical trials and real-world studies that validate device safety and efficacy. According to Datavagyanik, such collaborations are instrumental in accelerating product approvals and broadening market access, particularly in emerging economies where regulatory pathways are evolving.

Expansion into Emerging Markets Accelerating Growth in the Stent Graft Market

While North America and Europe have historically led the Stent Graft Market, the focus is now shifting toward Asia-Pacific and Latin American regions. These geographies are witnessing rapid infrastructure development in healthcare, along with increasing government investments and favorable demographic profiles.

For instance, countries like China and India are experiencing a notable surge in aortic aneurysm diagnoses, driven by improved healthcare access and expanding insurance coverage. Datavagyanik indicates that the Stent Graft Market in Asia-Pacific is expected to register a CAGR of over 8% through 2030, significantly outpacing growth in mature markets. Local manufacturing and public-private partnerships are further supporting cost-effective stent graft production and widespread distribution.

Application-Specific Expansion Broadening the Scope of the Stent Graft Market

The Stent Graft Market is diversifying beyond traditional aneurysm repair. New applications in the management of traumatic aortic injuries, dissections, and complex peripheral arterial diseases are increasing the clinical utility of these devices. For instance, thoracic stent grafts are now frequently deployed in emergency settings to treat blunt aortic injuries resulting from vehicular accidents.

Additionally, the increasing incidence of renal and visceral artery aneurysms is prompting the use of branched stent grafts. Datavagyanik highlights that multidisciplinary treatment protocols involving interventional radiologists and vascular surgeons are playing a pivotal role in expanding clinical indications, thereby boosting demand in niche yet high-risk patient segments.

Regulatory Approvals and Clinical Trials Strengthening the Stent Graft Market

Regulatory bodies across the globe are fast-tracking approval processes for innovative stent graft solutions, especially those addressing unmet clinical needs. In recent years, the U.S. FDA and the European Medicines Agency (EMA) have both granted breakthrough device designation and CE marks to multiple next-generation stent graft products.

For example, Medtronic’s Valiant Navion Thoracic Stent Graft System received FDA approval based on its favorable clinical trial outcomes, which demonstrated over 90% freedom from major adverse events at 12 months. Datavagyanik notes that such regulatory support not only accelerates market entry but also builds physician confidence in adopting newer technologies, further energizing the Stent Graft Market.

Stent Graft Market Size Reflects Consistent Upward Trajectory

As per estimates compiled by Datavagyanik, the global Stent Graft Market Size exceeded USD 2.4 billion in 2023 and is projected to reach over USD 4 billion by 2030. This growth trajectory is underpinned by rising procedural volumes, continuous product innovation, and expanding geographic footprints. Notably, thoracic stent grafts represent the fastest-growing segment, driven by their increasing use in both elective and emergency interventions.

Further dissecting the data, hospital-based endovascular centers currently account for the largest share of market volume, but ambulatory surgical centers are expected to witness the fastest growth over the next five years. This shift is aligned with broader healthcare trends toward outpatient care and cost-efficient service delivery models.

Digital Integration and AI-Driven Planning Tools Supporting the Stent Graft Market

Digital transformation in healthcare is offering additional momentum to the Stent Graft Market. AI-driven software tools are increasingly being used for preoperative planning, simulation, and post-operative monitoring of stent graft procedures. These platforms enable enhanced visualization, sizing accuracy, and patient-specific customization, significantly reducing the risk of endoleaks and device migration.

For instance, AI-based planning systems can process complex anatomical data to recommend optimal stent graft configurations, reducing procedural times and improving outcomes. Datavagyanik points out that such digital advancements are gaining traction among leading vascular surgery centers, further streamlining the patient journey and increasing procedural confidence.

“Track Country-wise Stent Graft Production and Demand through our Database”

- - Stent Graft sales volume database for 28+ countries worldwide

North America Dominates Global Demand in the Stent Graft Market

North America continues to lead the global Stent Graft Market, driven by a high prevalence of aortic aneurysms, well-established healthcare infrastructure, and early adoption of minimally invasive surgical techniques. Datavagyanik estimates that over 60,000 abdominal aortic aneurysm repairs are conducted annually in the United States, with more than 75% performed using endovascular techniques involving stent grafts. This demand is reinforced by the aging population, with over 17% of U.S. residents currently above 65 years—a demographic highly susceptible to aneurysmal conditions.

For instance, the increasing use of thoracic stent grafts in trauma cases and dissections has expanded clinical utility in both urban trauma centers and specialized cardiovascular units. Reimbursement support for EVAR and TEVAR procedures, coupled with favorable regulatory mechanisms such as FDA’s breakthrough device designation, continues to position North America at the forefront of the global Stent Graft Market.

Expanding Patient Pools Fueling Growth in Asia-Pacific Stent Graft Market

The Asia-Pacific region is emerging as a highly lucrative zone within the global Stent Graft Market. Countries such as China, India, and Japan are witnessing a surge in endovascular procedures, driven by rising awareness, urbanization, and improving access to specialized vascular care. For example, Datavagyanik reports that China is now performing over 20,000 stent graft implantations annually—a figure expected to double by 2030.

Several factors contribute to this growth. Rapid expansion of tertiary care hospitals, growing government healthcare expenditure, and increasing prevalence of hypertension and smoking-related vascular diseases are key. For instance, Japan’s rapidly aging society, where nearly 29% of the population is above 65, provides a large patient base. Additionally, localized product development and clinical trials, especially in India and South Korea, are contributing to cost-effective innovations that are expanding the regional Stent Graft Market.

Europe’s Technological Leadership Supporting Steady Stent Graft Market Growth

Europe plays a pivotal role in driving technological innovation in the global Stent Graft Market. Countries like Germany, France, and the UK are home to some of the world’s leading vascular centers and medical device innovators. For example, Germany alone performs more than 15,000 EVAR procedures each year, driven by an advanced clinical network and widespread use of 3D imaging technologies for procedural planning.

Datavagyanik notes that the presence of regional manufacturing facilities and academic partnerships has enabled European firms to push the boundaries of stent graft design—especially in the fenestrated and branched device categories. Additionally, post-market surveillance and patient registries in this region are helping to generate real-world performance data, further accelerating adoption and product refinements.

Latin America and Middle East Gaining Momentum in the Stent Graft Market

While smaller in current scale, the Stent Graft Market in Latin America and the Middle East is gaining pace. Brazil and Mexico are leading the charge in Latin America with increasing numbers of interventional radiologists and vascular surgeons adopting endovascular repair procedures. For instance, the annual growth in EVAR procedures in Brazil exceeds 7%, fueled by public-private investments in hybrid operating rooms.

In the Middle East, countries such as Saudi Arabia and the UAE are heavily investing in high-end medical infrastructure. Datavagyanik highlights that collaborations between international manufacturers and local healthcare institutions are making advanced stent graft technologies more accessible. These emerging regions represent significant untapped potential for future expansion.

Complex Multi-Level Segmentation Defining the Stent Graft Market

The Stent Graft Market is segmented across several layers, including product type, material, application, end user, and geography. Product-wise, bifurcated stent grafts continue to hold the largest market share due to their widespread use in abdominal aortic aneurysm repairs. However, branched and fenestrated devices are gaining rapid adoption, particularly in complex aortic anatomies where customization is critical.

From a material standpoint, the preference for expanded polytetrafluoroethylene (ePTFE) and polyester continues due to their durability and biocompatibility. For instance, polyester-based stent grafts are widely used in thoracic applications due to their strength under high-pressure vascular conditions. Datavagyanik reports that the demand for hybrid-material stent grafts is growing, especially in markets that emphasize long-term patency and resistance to infection.

In terms of application, the abdominal aortic aneurysm (AAA) segment dominates, but thoracic aortic aneurysm (TAA) applications are registering higher year-over-year growth. Emerging applications in trauma, dissection, and visceral artery repair are also expanding the clinical footprint of stent graft technology.

Public and Private Hospitals Leading End-User Demand in the Stent Graft Market

Hospitals remain the largest end-user segment in the Stent Graft Market due to their superior surgical infrastructure and specialist availability. Datavagyanik emphasizes that high-volume hospitals in urban areas perform the majority of complex stent graft procedures, particularly those requiring hybrid operating environments with real-time imaging.

However, ambulatory surgical centers (ASCs) are showing promising growth in select developed markets where minimally invasive procedures are being shifted to outpatient settings. For example, in the U.S., reimbursement support and cost-efficiency measures are prompting insurers and providers to favor ASCs for uncomplicated EVAR procedures. This shift is gradually redistributing procedural volumes and reshaping demand patterns in the Stent Graft Market.

Stent Graft Manufacturing Innovation Enhancing Global Supply Chain Efficiency

The evolution of Stent Graft Manufacturing is playing a critical role in addressing global demand. Key players are shifting toward lean, digitized manufacturing models that reduce production lead times and enhance product customization. For instance, modular manufacturing platforms enable real-time assembly of patient-specific devices, reducing the inventory burden for hospitals and distributors.

Datavagyanik identifies 3D printing and robotic-assisted stent graft assembly as two game-changing trends in the Stent Graft Manufacturing ecosystem. These innovations allow for micro-precision and design flexibility while maintaining compliance with stringent regulatory standards. Manufacturers in regions like Europe and the U.S. are also increasingly outsourcing components to Asia to balance cost and speed-to-market, creating a hybridized global production model.

Regional Hubs Emerging as Centers of Excellence in Stent Graft Manufacturing

Countries like Germany, Ireland, and Singapore are emerging as regional hubs for Stent Graft Manufacturing due to their strong regulatory systems, skilled workforce, and government support for medical device innovation. For example, Singapore has built a MedTech ecosystem that supports rapid prototyping, regulatory consulting, and export facilitation—all of which are vital for competitive manufacturing.

Meanwhile, large-scale production centers in China and India are optimizing costs through high-volume batch manufacturing. Datavagyanik highlights that localized Stent Graft Manufacturing in these countries is also helping global players meet domestic demand with shorter distribution cycles and lower import duties.

Pricing Trends in the Stent Graft Market Reflect Cost vs. Innovation Balance

Pricing dynamics in the Stent Graft Market are shaped by a balance between technological sophistication and competitive cost pressures. On average, the cost of a standard abdominal stent graft ranges from USD 5,000 to USD 10,000, while fenestrated and branched grafts can exceed USD 15,000 due to their customization requirements.

Datavagyanik notes that despite these high device costs, hospitals are realizing long-term savings through reduced hospital stays, fewer complications, and lower reintervention rates. For example, studies show that patients receiving endovascular aneurysm repair are discharged up to three days earlier on average compared to open surgical repair—offsetting device costs through operational savings.

Bulk purchasing agreements, value-based procurement, and regional manufacturing are also helping bring down per-unit costs in developing markets. For instance, government tenders in countries like India and Brazil often negotiate prices up to 30% lower than Western markets, enabling broader access while maintaining market viability.

Outlook on Value-Based Pricing Reshaping the Stent Graft Market

Value-based healthcare models are beginning to influence pricing and reimbursement trends in the Stent Graft Market. Rather than focusing solely on upfront device costs, payers and providers are increasingly evaluating long-term outcomes, including reduced reintervention rates, improved patient quality of life, and minimized hospital readmissions.

Manufacturers that can demonstrate clinical and economic value through real-world data and post-market studies are better positioned to maintain premium pricing. Datavagyanik projects that bundled payment models and performance-based reimbursement will become more prominent by the end of the decade, fundamentally reshaping pricing strategies across the Stent Graft Market.

“Stent Graft Manufacturing Database”

- - Stent Graft top manufacturers market share for 28+ manufacturers
  - Top 8 manufacturers and top 18 manufacturers of Stent Graft in North America, Europe, Asia Pacific
  - Stent Graft sales dashboard, Stent Graft sales data in excel format

Leading Manufacturers in the Stent Graft Market

The Stent Graft Market is characterized by a competitive landscape dominated by several key players, each contributing significantly to market dynamics through innovative product offerings and strategic initiatives.

Medtronic plc stands as a prominent leader, offering a comprehensive portfolio that includes the Endurant™ II for abdominal aortic aneurysms (AAA) and the Valiant™ Navion for thoracic aortic aneurysms (TAA). These products are renowned for their advanced delivery systems and adaptability to complex anatomies, reinforcing Medtronic’s strong market presence.
L. Gore & Associates is another major contributor, known for its GORE® EXCLUDER® AAA Endoprosthesis and the GORE® TAG® Thoracic Endoprosthesis. These devices are recognized for their durability and ease of deployment, catering to a wide range of patient needs.

Cook Medical offers the Zenith® series, including the Zenith Flex® and Zenith Alpha™ Thoracic Endovascular Graft. These products are designed for precision and reliability, addressing both standard and complex cases in the Stent Graft Market.

Terumo Corporation has made significant strides with its TREO™ Abdominal Stent-Graft System and the RELAY® Thoracic Stent-Graft System. These offerings emphasize flexibility and conformability, essential for treating diverse patient anatomies.

Endologix LLC focuses on AAA treatment with its AFX®2 Endovascular AAA System and the ALTO® Abdominal Stent Graft System. These devices are tailored for challenging anatomies, enhancing Endologix’s position in the market.

Artivion, Inc., formerly known as CryoLife, provides the E-nside® and E-tegra® stent graft systems, catering to both standard and complex aortic repairs. Their emphasis on customization and patient-specific solutions contributes to their growing market share.

MicroPort Scientific Corporation has expanded its global footprint through acquisitions and offers the Hercules™ Thoracic Stent Graft System. Their focus on innovation and affordability makes them a notable player, especially in emerging markets.

JOTEC GmbH, a subsidiary of Artivion, specializes in complex aortic and peripheral vascular diseases, offering products like the E-liac® and E-xtra Design Engineering for customized solutions.

Lombard Medical Technologies provides the Aorfix™ Endovascular Stent Graft, designed to accommodate highly angulated necks, addressing a specific niche within the Stent Graft Market.

LifeTech Scientific Corporation has a diverse product range, including thoracic and abdominal stent grafts, with a strong presence in the Asia-Pacific region, contributing to the market’s growth in emerging economies.

Market Share Distribution Among Manufacturers

In the Stent Graft Market, market share is influenced by factors such as product innovation, clinical outcomes, and global reach. Medtronic leads with a substantial share, attributed to its extensive product line and global distribution network. W. L. Gore & Associates follows closely, with its products widely adopted due to their reliability and performance.

Cook Medical holds a significant share, especially in the AAA segment, owing to its Zenith® series. Terumo Corporation’s market share is bolstered by its strong presence in Asia and innovative product offerings.

Endologix maintains a focused share in the AAA market, while Artivion’s growth is driven by its customized solutions for complex cases. MicroPort’s strategic acquisitions and cost-effective products have enhanced its market position, particularly in price-sensitive regions.

JOTEC GmbH and Lombard Medical Technologies serve specialized segments, with products designed for specific anatomical challenges, contributing to their niche market shares. LifeTech Scientific’s emphasis on emerging markets has led to a growing share in the Asia-Pacific region.

Recent Developments in the Stent Graft Market

The Stent Graft Market has witnessed several notable developments:

In August 2024, Terumo India launched the TREO™ Stent-Graft System, enhancing its EVAR portfolio and addressing the needs of patients with challenging anatomies.

In July 2024, Endospan secured additional funding from Artivion to support the FDA approval process for its Nexus™ Stent Graft System, aimed at treating aortic arch pathologies.

In January 2024, W. L. Gore & Associates received FDA approval for a lower-profile version of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis, expanding treatment options for complex vascular diseases.

In June 2023, Endospan presented initial European experiences with its NEXUS DUO™ Aortic Arch Stent Graft System, showcasing its potential in treating complex aortic arch diseases.

In May 2021, Endologix announced the first implant of its ALTO® Abdominal Stent Graft in Canada, following Health Canada approval, marking a significant milestone in its international expansion.

These developments underscore the dynamic nature of the Stent Graft Market, with manufacturers continually innovating to address unmet clinical needs and expand their global presence.